pH-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma

J Biomater Appl. 2019 Aug;34(2):219-228. doi: 10.1177/0885328219849711. Epub 2019 May 13.
No abstract available

Keywords: Hepatocellular carcinoma; cisplatin; hyaluronic acid; pH-responsive release; sorafenib.

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacokinetics
  • Carcinoma, Hepatocellular / drug therapy*
  • Cell Membrane Permeability
  • Cell Survival
  • Cisplatin / adverse effects
  • Cisplatin / chemistry*
  • Cisplatin / pharmacokinetics
  • Delayed-Action Preparations / chemistry
  • Drug Liberation
  • Drug Therapy, Combination / methods
  • Hep G2 Cells
  • Humans
  • Hyaluronic Acid / chemistry*
  • Hydrogen-Ion Concentration
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms, Experimental / drug therapy
  • Mice, Nude
  • Nanocapsules / chemistry*
  • Sorafenib / adverse effects
  • Sorafenib / chemistry*
  • Sorafenib / pharmacokinetics

Substances

  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Nanocapsules
  • Hyaluronic Acid
  • Sorafenib
  • Cisplatin